首页> 外文期刊>Archives of disease in childhood >Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis.
【24h】

Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis.

机译:结肠壁厚度,胰酶剂量和囊性纤维化制剂的类型。

获取原文
获取原文并翻译 | 示例
       

摘要

Increased colonic wall thickness has been reported in patients exposed to large doses of high strength pancreatic enzyme preparations who did not develop fibrosing colonopathy. This has been interpreted as evidence for a spectrum of subclinical disease. The relation between sonographically measured colonic wall thickness and pancreatic enzyme preparation and dose was studied in 86 children with cystic fibrosis (CF). Colonic wall thickness of a control group was also measured. The average thickness in all colonic regions was higher in the CF group (overall average range 0.7-2.5 mm v 0.6-1.4 mm in the control group). There was no significant relation between colonic wall thickness and age, sex, total dose of lipase, or copolymer. Apart from one patient with an early colonic stricture, none of those exposed to high doses of lipase, or the methacrylic acid copolymer Eudragit L30 D55, showed evidence of subclinical damage to the colon. The reproducibility of the sonographic measurements was poor.
机译:据报道,暴露于大剂量高强度胰酶制剂且未发生纤维化结肠病的患者结肠壁厚度增加。这已被解释为一系列亚临床疾病的证据。超声检查了86例囊性纤维化(CF)患儿的超声测量结肠壁厚度与胰酶制剂和剂量之间的关系。还测量了对照组的结肠壁厚度。 CF组所有结肠区域的平均厚度均较高(总体平均范围为0.7-2.5 mm,对照组为0.6-1.4 mm)。结肠壁厚度与年龄,性别,脂肪酶总剂量或共聚物之间无显着关系。除了一名患有早期结肠狭窄的患者外,没有人暴露于高剂量的脂肪酶或甲基丙烯酸共聚物Eudragit L30 D55中,没有显示出对结肠的亚临床损害的证据。超声检查的可重复性很差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号